At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 650 enrolled
Drug / intervention
Drotaverine hydrochloride +1 moredrug
Likely dose
Drotaverine hydrochloride 40mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Drotaverine Hydrochloride Versus Hyoscine-N-butylbromide for Duodenal Antimotility During ERCP: a Prospective, Multicenter Randomized Controlled Trial
In Brief
A Phase 3 clinical trial evaluating Drotaverine hydrochloride and Hyoscine-N-butylbromide for ERCP and 2 related conditions. Completed, enrolled 650 participants across 4 sites.
Detailed Summary
The aim of the present study was to evaluate the use of drotaverine hydrochloride versus hyoscine-N-butylbromide in reducing duodenal motility during diagnostic and therapeutic ERCP.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsERCP, Pancreatic Diseases, Bile Duct Diseases
CountriesChina
Collaborators--
Timeline
Phase 3CompletedFinished
2009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2008
First PostedAug 2008
Primary CompletionMar 2009
Study CompletionJul 2009
TodayJul 2026
First PostedAug 8, 2008
Enrollment StartAug 1, 2008
Primary CompletionMar 1, 2009
Study CompletionJul 1, 2009
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 17.9 years ago
Interventions
Drotaverine hydrochloridedrug
Drotaverine hydrochloride 40mg was administered intravenously 15 minutes before ERCP
Hyoscine-N-butylbromidedrug
Hyoscine-N-butylbromide 20mg was administered intravenously 15 minutes before ERCP.